Funder
AbbVie
Australian Government Department of Health and Ageing
National Health and Medical Research Council Career Development Fellowship
National Health and Medical Research Council Practitioner Research Fellowship
National Health and Medical Research Council Early Career Fellowship
Subject
Health Policy,Medicine (miscellaneous)
Reference57 articles.
1. Recommendations for testing, managing, and treating hepatitis C;AASLD/IDSA,2015
2. Long-term clinical outcomes in HCV genotype 1-infected patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir ± ribavirin: First interim safety and efficacy results from TOPAZ-I;Agarwal;Hepatology,2016
3. Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian trial in acute hepatitis C;Alavi;International Journal on Drug Policy,2015
4. Factors associated with treatment failure of patients with psychiatric diseases and injecting drug users in the treatment of genotype 2 or 3 hepatitis C chronic infection;Alvarez-Uria;Liver International,2009
5. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection;Andreone;Gastroenterology,2014
Cited by
23 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献